These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 39170961)

  • 21. Risk of waning humoral responses after inactivated or subunit recombinant SARS-CoV-2 vaccination in patients with chronic diseases: Findings from a prospective observational study in China.
    Li H; Cai D; Jiang D; Li X; Liao X; Liu D; Liu Z; Zhu P; Yin G; Ming J; Peng M; Chen M; Ling N; Lan Y; Zhang D; Hu P; Ren H
    J Med Virol; 2023 Jan; 95(1):e28434. PubMed ID: 36571260
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody Responses and the Effects of Clinical Drugs in COVID-19 Patients.
    Wei L; Shang Y; Liu X; Li X; Chen G; Liang S; Zou Z; Ding T; Hong Z; Wu M; Xia J
    Front Immunol; 2021; 12():580989. PubMed ID: 34177879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sustainability of SARS-CoV-2 Induced Humoral Immune Responses in COVID-19 Patients from Hospitalization to Convalescence Over Six Months.
    Zheng Y; Zhang Q; Ali A; Li K; Shao N; Zhou X; Ye Z; Chen X; Cao S; Cui J; Zhou J; Wang D; Hou B; Li M; Cui M; Deng L; Sun X; Zhang Q; Yang Q; Li Y; Wang H; Lei Y; Yu B; Cheng Y; Tong X; Men D; Zhang XE
    Virol Sin; 2021 Oct; 36(5):869-878. PubMed ID: 33661489
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Humoral immune responses in hospitalized COVID-19 patients.
    Mahallawi WH
    Saudi J Biol Sci; 2021 Jul; 28(7):4055-4061. PubMed ID: 33935561
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dynamics of Different Classes and Subclasses of Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Variants after Coronavirus Disease 2019 and CoronaVac Vaccination in Thailand.
    Poolchanuan P; Matsee W; Sengyee S; Siripoon T; Dulsuk A; Phunpang R; Pisutsan P; Piyaphanee W; Luvira V; Chantratita N
    mSphere; 2023 Feb; 8(1):e0046522. PubMed ID: 36688637
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19.
    Wu J; Liang B; Chen C; Wang H; Fang Y; Shen S; Yang X; Wang B; Chen L; Chen Q; Wu Y; Liu J; Yang X; Li W; Zhu B; Zhou W; Wang H; Li S; Lu S; Liu D; Li H; Krawczyk A; Lu M; Yang D; Deng F; Dittmer U; Trilling M; Zheng X
    Nat Commun; 2021 Mar; 12(1):1813. PubMed ID: 33753738
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients.
    Iyer AS; Jones FK; Nodoushani A; Kelly M; Becker M; Slater D; Mills R; Teng E; Kamruzzaman M; Garcia-Beltran WF; Astudillo M; Yang D; Miller TE; Oliver E; Fischinger S; Atyeo C; Iafrate AJ; Calderwood SB; Lauer SA; Yu J; Li Z; Feldman J; Hauser BM; Caradonna TM; Branda JA; Turbett SE; LaRocque RC; Mellon G; Barouch DH; Schmidt AG; Azman AS; Alter G; Ryan ET; Harris JB; Charles RC
    Sci Immunol; 2020 Oct; 5(52):. PubMed ID: 33033172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody response and risk of reinfection over 2 years among the patients with first wave of COVID-19.
    Peghin M; De Martino M; Palese A; Chiappinotto S; Fonda F; Gerussi V; Sartor A; Curcio F; Grossi PA; Isola M; Tascini C
    Clin Microbiol Infect; 2024 Apr; 30(4):522-530. PubMed ID: 38141821
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
    Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
    Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SARS-CoV-2 Infection-and mRNA Vaccine-induced Humoral Immunity among Schoolchildren in Hawassa, Ethiopia.
    Merid Y; Tekleselasie W; Tesfaye E; Gadisa A; Fentahun D; Abate A; Alemu A; Mihret A; Mulu A; Gelanew T
    Front Immunol; 2023; 14():1163688. PubMed ID: 37398668
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hospitalisations and humoral COVID-19 vaccine response in vaccinated rituximab-treated multiple sclerosis patients.
    Torgauten HM; Onyango TB; Ljostveit S; Hallin EI; Serkland TT; Skrede S; Langeland N; Cox RJ; Wergeland S; Myhr KM; Torkildsen Ø
    Mult Scler Relat Disord; 2024 Sep; 89():105770. PubMed ID: 39029342
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimisation and Validation of a conventional ELISA and cut-offs for detecting and quantifying anti-SARS-CoV-2 Spike, RBD, and Nucleoprotein IgG, IgM, and IgA antibodies in Uganda.
    Oluka GK; Namubiru P; Kato L; Ankunda V; Gombe B; Cotten M; ; Musenero M; Kaleebu P; Fox J; Serwanga J
    Front Immunol; 2023; 14():1113194. PubMed ID: 36999017
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibody response to multiple antigens of SARS-CoV-2 in patients with diabetes: an observational cohort study.
    Lampasona V; Secchi M; Scavini M; Bazzigaluppi E; Brigatti C; Marzinotto I; Davalli A; Caretto A; Laurenzi A; Martinenghi S; Molinari C; Vitali G; Di Filippo L; Mercalli A; Melzi R; Tresoldi C; Rovere-Querini P; Landoni G; Ciceri F; Bosi E; Piemonti L
    Diabetologia; 2020 Dec; 63(12):2548-2558. PubMed ID: 33029657
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod.
    Capuano R; Bisecco A; Conte M; Donnarumma G; Altieri M; Grimaldi E; Franci G; Chianese A; Galdiero M; Coppola N; Tedeschi G; Gallo A
    Mult Scler Relat Disord; 2022 Apr; 60():103724. PubMed ID: 35272145
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Combination of N and S Antigens With IgA and IgG Measurement Strengthens the Accuracy of SARS-CoV-2 Serodiagnostics.
    Jalkanen P; Pasternack A; Maljanen S; Melén K; Kolehmainen P; Huttunen M; Lundberg R; Tripathi L; Khan H; Ritvos MA; Naves R; Haveri A; Österlund P; Kuivanen S; Jääskeläinen AJ; Kurkela S; Lappalainen M; Rantasärkkä K; Vuorinen T; Hytönen J; Waris M; Tauriainen S; Ritvos O; Kakkola L; Julkunen I
    J Infect Dis; 2021 Jul; 224(2):218-228. PubMed ID: 33905505
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A cohort analysis of SARS-CoV-2 anti-spike protein receptor binding domain (RBD) IgG levels and neutralizing antibodies in fully vaccinated healthcare workers.
    Padoan A; Cosma C; Della Rocca F; Barbaro F; Santarossa C; Dall'Olmo L; Galla L; Cattelan A; Cianci V; Basso D; Plebani M
    Clin Chem Lab Med; 2022 Jun; 60(7):1110-1115. PubMed ID: 35473824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Seropositivity and neutralising antibodies at six months after BNT162b2 vaccination in patients with solid tumours.
    Margalit O; Shacham-Shmueli E; Itay A; Berger R; Halperin S; Jurkowicz M; Levin EG; Olmer L; Regev-Yochay G; Lustig Y; Rahav G
    Eur J Cancer; 2022 Jun; 168():51-55. PubMed ID: 35439660
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis.
    Farroni C; Picchianti-Diamanti A; Aiello A; Nicastri E; Laganà B; Agrati C; Castilletti C; Meschi S; Colavita F; Cuzzi G; Casetti R; Grassi G; Petrone L; Vanini V; Salmi A; Repele F; Altera AMG; Maffongelli G; Corpolongo A; Salemi S; Di Rosa R; Nalli G; Sesti G; Vaia F; Puro V; Goletti D
    Front Immunol; 2022; 13():846753. PubMed ID: 35309297
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of Serological Biomarkers of SARS-CoV-2 Infection in Convalescent Samples From Severe, Moderate and Mild COVID-19 Cases.
    Castillo-Olivares J; Wells DA; Ferrari M; Chan ACY; Smith P; Nadesalingam A; Paloniemi M; Carnell GW; Ohlendorf L; Cantoni D; Mayora-Neto M; Palmer P; Tonks P; Temperton NJ; Peterhoff D; Neckermann P; Wagner R; Doffinger R; Kempster S; Otter AD; Semper A; Brooks T; Albecka A; James LC; Page M; Schwaeble W; Baxendale H; Heeney JL
    Front Immunol; 2021; 12():748291. PubMed ID: 34867975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.